By: IPP Bureau
Last updated : August 16, 2023 10:32 am
The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
Global pharma major Lupin Limited (Lupin) has announced that its Unit-2 manufacturing facility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (U.S. FDA). The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
"We are pleased to announce that the U.S. FDA inspection of our Mandideep Unit-2 facility concluded with no observations. This further reaffirms our commitment to superior quality and compliance standards," said Nilesh Gupta, Managing Director, Lupin.